Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):1146-1157. doi: 10.26355/eurrev_202101_24685.
Many studies have been published recently on the characteristics of the clinical manifestations of COVID-19 in children. The quality scores of literature are different, and the incidence of clinical manifestations and laboratory tests results vary greatly. Therefore, a systematic retrospective meta-analysis is needed to determine the incidence of the clinical manifestations of COVID-19 in children.
Data from databases, such as PubMed, Web of science, EMBASE, Johns Hopkins University, and Chinese databases were analysed from January 31, 2020 to October 20, 2020. High-quality articles were selected for analysis based on a quality standard score. A meta-analysis of random effects was used to determine the prevalence of comorbidities and subgroup meta-analysis to examine the changes in the estimated prevalence in different subgroups.
Seventy-one articles involving 11,671 children were included in the study. The incidence of fever, respiratory symptoms, gastrointestinal symptoms, asymptomatic patients, nervous system symptoms, and chest tightness was 55.8%, 56.8%, 14.4%, 21.1%, 6.7%, and 6.1%, respectively. The incidence of multisystem inflammatory syndrome was 6.2%. Laboratory examination results showed that lymphocytes decreased in 12% and leukocytes decreased in 8.8% of patients, whereas white blood cells increased in 7.8% of patients. Imaging showed abnormalities in 66.5%, and ground-glass opacities were observed in 36.9% patients. Epidemiological history was present in 85.2% cases; severe disease rate was 3.33%. The mortality rate was 0.28%.
The clinical symptoms of COVID-19 in children are mild, and laboratory indicators and imaging manifestations are atypical. While screening children for COVID-19, in addition to assessing patients for symptoms as the first step of screening, the epidemiological history of patients should be obtained.
最近有许多关于儿童 COVID-19 临床表现特征的研究发表。文献的质量评分不同,临床表现和实验室检查结果的发生率也有很大差异。因此,需要进行系统的回顾性荟萃分析,以确定儿童 COVID-19 的临床表现发生率。
从 2020 年 1 月 31 日至 2020 年 10 月 20 日,对 PubMed、Web of science、EMBASE、约翰霍普金斯大学和中国数据库等数据库的数据进行分析。根据质量标准评分选择高质量文章进行分析。使用随机效应荟萃分析确定合并症的患病率,并进行亚组荟萃分析以检查不同亚组中估计患病率的变化。
研究纳入了 71 篇涉及 11671 名儿童的文章。发热、呼吸道症状、胃肠道症状、无症状患者、神经系统症状和胸闷的发生率分别为 55.8%、56.8%、14.4%、21.1%、6.7%和 6.1%。多系统炎症综合征的发生率为 6.2%。实验室检查结果显示,12%的患者淋巴细胞减少,8.8%的患者白细胞减少,而 7.8%的患者白细胞增多。影像学检查显示异常的占 66.5%,磨玻璃影占 36.9%。85.2%的病例有流行病学史;重症率为 3.33%。死亡率为 0.28%。
儿童 COVID-19 的临床症状较轻,实验室指标和影像学表现不典型。在对儿童 COVID-19 进行筛查时,除了评估患者的症状作为筛查的第一步外,还应获取患者的流行病学史。